Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Bio-Rad Laboratories (BIO) Share Price
Media headlines about Bio-Rad Laboratories (NYSE:BIO) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 48.0311778632151 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- Blood Transfusion Diagnostics Market ; Distribution Channel – Hospitals … (markets.businessinsider.com)
- Bio Rad Laboratories : Plex 200 System (4-traders.com)
- Latin America Genomics Market is estimated to be growing at a CAGR of 9.1% | Market Data Forecast (medgadget.com)
- Global Microfluidics Market Professional Survey Report 2017: By Product, Application, Manufacturer, Sales and Segmentation (mynewsdesk.com)
- Alcohol Breathalyzer and Drug Testing Equipment Global Market by Technique & Data Validation, Analysis and Forecasts to 2022 (emailwire.com)
BIO has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and lowered their target price for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price on the stock. Finally, Jefferies Group LLC restated a “buy” rating and set a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Bio-Rad Laboratories has a consensus rating of “Buy” and an average target price of $228.80.
Bio-Rad Laboratories (NYSE:BIO) opened at 220.47 on Thursday. Bio-Rad Laboratories has a one year low of $154.89 and a one year high of $242.79. The firm has a market capitalization of $6.53 billion, a P/E ratio of 435.71 and a beta of 0.93. The company’s 50-day moving average is $222.21 and its 200-day moving average is $216.79.
In related news, EVP Michael Crowley sold 700 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 28.29% of the company’s stock.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.